

Lucio Oldani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4404575/publications.pdf>

Version: 2024-02-01

41
papers

1,292
citations

471509

17
h-index

361022

35
g-index

47
all docs

47
docs citations

47
times ranked

1998
citing authors

#	ARTICLE	IF	CITATIONS
1	A 6-month follow-up study on response and relapse rates following an acute trial of repetitive transcranial magnetic stimulation in patients with major depression. <i>CNS Spectrums</i> , 2022, 27, 93-98.	1.2	6
2	Genome-wide association study detected novel susceptibility genes for social cognition impairment in people with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 46-54.	2.6	4
3	Accuracy of self-assessment of real-life functioning in schizophrenia. <i>NPJ Schizophrenia</i> , 2021, 7, 11.	3.6	18
4	Impact of the first Covid-19 pandemic wave on first episode psychosis in Milan, Italy. <i>Psychiatry Research</i> , 2021, 298, 113802.	3.3	33
5	Factors Associated With Real-Life Functioning in Persons With Schizophrenia in a 4-Year Follow-up Study of the Italian Network for Research on Psychoses. <i>JAMA Psychiatry</i> , 2021, 78, 550.	11.0	89
6	A case of treatment-resistant bipolar depression and comorbid OCD treated with deep brain stimulation of the medial forebrain bundle: 5-year follow-up results. <i>Journal of Clinical Neuroscience</i> , 2021, 89, 103-105.	1.5	4
7	Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life". <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 109, 110250.	4.8	18
8	The interplay among psychopathology, personal resources, context-related factors and real-life functioning in schizophrenia: stability in relationships after 4 years and differences in network structure between recovered and non-recovered patients. <i>World Psychiatry</i> , 2020, 19, 81-91.	10.4	96
9	The association between insight and depressive symptoms in schizophrenia: Undirected and Bayesian network analyses. <i>European Psychiatry</i> , 2020, 63, 1-21.	0.2	30
10	The influence of autistic symptoms on social and non-social cognition and on real-life functioning in people with schizophrenia: Evidence from the Italian Network for Research on Psychoses multicenter study. <i>European Psychiatry</i> , 2020, 63, e98.	0.2	20
11	Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. <i>Human Psychopharmacology</i> , 2019, 34, e2695.	1.5	6
12	The metabolic basis of psychosis in bipolar disorder: A positron emission tomography study. <i>Bipolar Disorders</i> , 2019, 21, 151-158.	1.9	10
13	Catatonia and Cotard's Syndrome. , 2019, , 189-208.		0
14	Cannabis-Induced Psychosis. , 2019, , 115-135.		1
15	New Directions in the Use of Brain Stimulation Interventions in Patients with Obsessive-Compulsive Disorder. <i>Current Medicinal Chemistry</i> , 2019, 25, 5712-5721.	2.4	4
16	The complex relationship between self-reported "personal recovery" and clinical recovery in schizophrenia. <i>Schizophrenia Research</i> , 2018, 192, 108-112.	2.0	45
17	Familial aggregation of MATRICS Consensus Cognitive Battery scores in a large sample of outpatients with schizophrenia and their unaffected relatives. <i>Psychological Medicine</i> , 2018, 48, 1359-1366.	4.5	37
18	Ten-year outcome of vagus nerve stimulation-implanted patients with treatment-resistant depression: two Italian cases. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 915-918.	2.2	2

#	ARTICLE	IF	CITATIONS
19	Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview. <i>Epidemiology and Psychiatric Sciences</i> , 2018, 27, 327-335.	3.9	57
20	Suicide attempts and clinical correlates in patients with bipolar I vs II disorder. <i>European Psychiatry</i> , 2018, 52, 113-115.	0.2	3
21	Premorbid academic and social functioning in patients with schizophrenia and its associations with negative symptoms and cognition. <i>Acta Psychiatrica Scandinavica</i> , 2018, 138, 253-266.	4.5	44
22	Disorganization and real-world functioning in schizophrenia: Results from the multicenter study of the Italian Network for Research on Psychoses. <i>Schizophrenia Research</i> , 2018, 201, 105-112.	2.0	52
23	A new tool to assess duration of untreated illness: Psychopathological Onset and Latency to Treatment Questionnaire (POLT-Q). <i>Rivista Di Psichiatria</i> , 2018, 53, 290-298.	0.6	1
24	Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. <i>International Journal of Clinical Practice</i> , 2017, 71, e12926.	1.7	7
25	Structural and metabolic differentiation between bipolar disorder with psychosis and substance-induced psychosis: An integrated MRI/PET study. <i>European Psychiatry</i> , 2017, 41, 85-94.	0.2	21
26	Personal resources and depression in schizophrenia: The role of self-esteem, resilience and internalized stigma. <i>Psychiatry Research</i> , 2017, 256, 359-364.	3.3	49
27	Reduced duration of untreated illness over time in patients with schizophrenia spectrum, mood and anxiety disorders. <i>Psychiatry and Clinical Neurosciences</i> , 2016, 70, 202-210.	1.8	17
28	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder?. <i>International Clinical Psychopharmacology</i> , 2016, 31, 347-352.	1.7	23
29	S-adenosyl methionine (SAME) for depression in adults. <i>The Cochrane Library</i> , 2016, 2016, CD011286.	2.8	48
30	Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. <i>Human Psychopharmacology</i> , 2016, 31, 113-120.	1.5	5
31	Brain stimulation treatments in bipolar disorder: A review of the current literature. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 482-494.	2.6	7
32	Differences in duration of untreated illness, duration, and severity of illness among clinical phenotypes of obsessive-compulsive disorder. <i>CNS Spectrums</i> , 2015, 20, 474-478.	1.2	16
33	Augmentative Repetitive Transcranial Magnetic Stimulation (rTMS) in the Acute Treatment of Poor Responder Depressed Patients: A Comparison Study Between High and Low Frequency Stimulation. <i>European Psychiatry</i> , 2015, 30, 271-276.	0.2	36
34	Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders. <i>International Clinical Psychopharmacology</i> , 2015, 30, 29-35.	1.7	13
35	Long-term Effects of Vagus Nerve Stimulation in Treatment-resistant Depression: A 5-year Follow up Case Series. <i>Brain Stimulation</i> , 2015, 8, 1229-1230.	1.6	9
36	A case of severe psychosis induced by novel recreational drugs. <i>F1000Research</i> , 2014, 3, 21.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Prevalence and disability of comorbid social phobia and obsessive-compulsive disorder in patients with panic disorder and generalized anxiety disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2014, 18, 248-254.	2.4	6
38	The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. <i>World Psychiatry</i> , 2014, 13, 275-287.	10.4	346
39	Vagus Nerve Stimulation in Treatment-Resistant Depression. <i>Journal of ECT</i> , 2013, 29, 41-44.	0.6	16
40	Physical health of patients with bipolar disorder. <i>Asia-Pacific Psychiatry</i> , 2013, 5, 4-6.	2.2	2
41	The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 723-732.	3.9	74